These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 31091761)

  • 1. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases.
    Noce A; Marrone G; Di Daniele F; Ottaviani E; Wilson Jones G; Bernini R; Romani A; Rovella V
    Nutrients; 2019 May; 11(5):. PubMed ID: 31091761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.
    Li HY; Zhou DD; Gan RY; Huang SY; Zhao CN; Shang A; Xu XY; Li HB
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling and harnessing the human gut microbiome in the rising burden of non-communicable diseases during urbanization.
    Huang Z; Li Y; Park H; Ho M; Bhardwaj K; Sugimura N; Lee HW; Meng H; Ebert MP; Chao K; Burgermeister E; Bhatt AP; Shetty SA; Li K; Wen W; Zuo T
    Gut Microbes; 2023; 15(1):2237645. PubMed ID: 37498052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota shaping - the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review.
    Baldi S; Mundula T; Nannini G; Amedei A
    World J Gastroenterol; 2021 Oct; 27(39):6715-6732. PubMed ID: 34754163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.
    Kanbay M; Onal EM; Afsar B; Dagel T; Yerlikaya A; Covic A; Vaziri ND
    Int Urol Nephrol; 2018 Aug; 50(8):1453-1466. PubMed ID: 29728993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics, prebiotics and amelioration of diseases.
    Tsai YL; Lin TL; Chang CJ; Wu TR; Lai WF; Lu CC; Lai HC
    J Biomed Sci; 2019 Jan; 26(1):3. PubMed ID: 30609922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota and probiotics intervention: A potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?
    Cavalcanti Neto MP; Aquino JS; Romão da Silva LF; de Oliveira Silva R; Guimarães KSL; de Oliveira Y; de Souza EL; Magnani M; Vidal H; de Brito Alves JL
    Pharmacol Res; 2018 Apr; 130():152-163. PubMed ID: 29410236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota and prebiotics modulation of uremic toxin generation.
    Koppe L; Fouque D
    Panminerva Med; 2017 Jun; 59(2):173-187. PubMed ID: 28001024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.
    Rukavina Mikusic NL; Kouyoumdzian NM; Choi MR
    Pflugers Arch; 2020 Mar; 472(3):303-320. PubMed ID: 32064574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Gut Microbiota in Kidney Disease: The Future in Renal Nutrition and Metabolism.
    Lambert K; Rinninella E; Biruete A; Sumida K; Stanford J; Raoul P; Mele MC; Wang AY; Mafra D
    J Ren Nutr; 2023 Nov; 33(6S):S30-S39. PubMed ID: 37632511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the Importance of Biotics in Gut Barrier Integrity.
    Kocot AM; Jarocka-Cyrta E; Drabińska N
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Renal Clinician's Guide to the Gut Microbiota.
    Snelson M; Biruete A; McFarlane C; Campbell K
    J Ren Nutr; 2020 Sep; 30(5):384-395. PubMed ID: 31928802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
    Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal microbiota alterations in chronic kidney disease and the influence of dietary components.
    Ondrussek-Sekac M; Navas-Carrillo D; Orenes-Piñero E
    Crit Rev Food Sci Nutr; 2021; 61(9):1490-1502. PubMed ID: 32393049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Gut Microbiome: A New Frontier in Cancer Diagnostics & Therapeutics.
    Rani V; Singhal S; Sharma K; Vaid R; Aggarwal K; Bhadana R; Agarwal R; Atale N
    Curr Pharm Des; 2021; 27(45):4578-4592. PubMed ID: 34620056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Microbiome and Uremic Solutes.
    Zaidan N; Nazzal L
    Toxins (Basel); 2022 Mar; 14(4):. PubMed ID: 35448854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gut dysbiotic microbiota-based hypothesis of human-to-human transmission of non-communicable diseases.
    Huang R; Ju Z; Zhou PK
    Sci Total Environ; 2020 Nov; 745():141030. PubMed ID: 32726703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.